Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
11.31
+0.36 (3.29%)
May 28, 2026, 1:02 PM EDT - Market open
Zevra Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Zevra Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $23. The average 1-year stock price forecast is 103.36% higher than the current stock price, while the lowest is $18 (+59.15%) and the highest is $26 (+129.89%).
Price Target: $23 (+103.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $25 | Buy | Maintains | $25 | +121.04% | May 8, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $23 → $25 | Buy | Maintains | $23 → $25 | +121.04% | May 8, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
Unknown Analyst Roth MKM No rating | Roth MKM | Buy Maintains $21 | Buy | Maintains | $21 | +85.68% | May 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $24 | Buy | Maintains | $24 | +112.20% | May 7, 2026 |
Financial Forecast
Revenue This Year
153.11M
from 106.47M
Increased by 43.81%
Revenue Next Year
222.87M
from 153.11M
Increased by 45.56%
EPS This Year
0.47
from 1.35
Decreased by -65.19%
EPS Next Year
1.46
from 0.47
Increased by 210.12%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 176.4M | 333.4M | ||||||
| Avg | 153.1M | 222.9M | ||||||
| Low | 132.7M | 170.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 65.7% | 117.7% | ||||||
| Avg | 43.8% | 45.6% | ||||||
| Low | 24.6% | 11.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.07 | 3.37 | ||||||
| Avg | 0.47 | 1.46 | ||||||
| Low | 0.15 | 0.50 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -20.7% | 617.2% | ||||||
| Avg | -65.2% | 210.1% | ||||||
| Low | -88.7% | 6.4% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.